On the public citation graph

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

https://doi.org/10.1007/s00280-014-2501-1
0 signed · 106 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 40 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-21): 10.1158/0008-5472.can-10-1296 (notice 2017-07-02).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/gcc.20155openalex-snapshot
Frequent DNA hypomethylation of human juxtacentromericBAGE loci in cancer
inferredcites →https://doi.org/10.1002/ijc.26320openalex-snapshot
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
inferredcites →https://doi.org/10.1002/pros.20665openalex-snapshot
Inducible expression of a prostate cancer‐testis antigen, SSX‐2, following treatment with a DNA methylation inhibitor
inferredcites →https://doi.org/10.1007/s00277-005-0008-xopenalex-snapshot
Decitabine: a historical review of the development of an epigenetic drug
inferredcites →https://doi.org/10.1016/0277-5379(87)90060-5openalex-snapshot
The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
inferredcites →https://doi.org/10.1016/j.ccr.2010.11.023openalex-snapshot
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
inferredcites →https://doi.org/10.1016/j.leukres.2010.02.004openalex-snapshot
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
inferredcites →https://doi.org/10.1016/s0168-9525(99)01971-xopenalex-snapshot
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
inferredcites →https://doi.org/10.1038/ng1089openalex-snapshot
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals
inferredcites →https://doi.org/10.1038/nrc2536openalex-snapshot
Insulin and insulin-like growth factor signalling in neoplasia
inferredcites →https://doi.org/10.1038/sj.bjc.6603024openalex-snapshot
Epigenetics as a mechanism driving polygenic clinical drug resistance
inferredcites →https://doi.org/10.1038/sj.bjc.6604932openalex-snapshot
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
inferredcites →https://doi.org/10.1038/sj.onc.1202059openalex-snapshot
Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression
inferredcites →https://doi.org/10.1038/sj.onc.1209072openalex-snapshot
Histone deacetylase inhibitor FK228 suppresses the Ras–MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma
inferredcites →https://doi.org/10.1073/pnas.180316197openalex-snapshot
Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation
inferredcites →https://doi.org/10.1074/jbc.c500186200openalex-snapshot
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
inferredcites →https://doi.org/10.1097/00000421-200210000-00015openalex-snapshot
Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix
inferredcites →https://doi.org/10.1097/00002371-199901000-00003openalex-snapshot
Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)
inferredcites →https://doi.org/10.1158/0008-5472.can-03-2629openalex-snapshot
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
inferredcites →https://doi.org/10.1158/0008-5472.can-03-3897openalex-snapshot
Overexpression of Histone Deacetylase 1 Confers Resistance to Sodium Butyrate–Mediated Apoptosis in Melanoma Cells through a p53-Mediated Pathway
inferredcites →https://doi.org/10.1158/0008-5472.can-05-1187openalex-snapshot
CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-05-3020openalex-snapshot
De novoInduction of a Cancer/Testis Antigen by 5-Aza-2′-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model
inferredcites →https://doi.org/10.1158/0008-5472.can-06-0080openalex-snapshot
Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms
inferredcites →https://doi.org/10.1158/0008-5472.can-06-2986openalex-snapshot
5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story
inferredcites →https://doi.org/10.1158/0008-5472.can-10-1296openalex-snapshot
Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-0669openalex-snapshot
Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura
inferredcites →https://doi.org/10.1158/1541-7786.mcr-04-0070openalex-snapshot
Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding
inferredcites →https://doi.org/10.1159/000074156openalex-snapshot
Drug Resistance in Human Melanoma: Mechanisms and Therapeutic Opportunities
inferredcites →https://doi.org/10.1182/blood-2003-03-0687openalex-snapshot
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
inferredcites →https://doi.org/10.1182/blood-2003-05-1738openalex-snapshot
Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease
inferredcites →https://doi.org/10.1182/blood-2005-11-4639openalex-snapshot
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells
inferredcites →https://doi.org/10.1182/blood-2007-10-117762openalex-snapshot
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells
inferredcites →https://doi.org/10.1182/blood.v120.21.1337.1337openalex-snapshot
Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
inferredcites →https://doi.org/10.1182/blood.v99.11.3905openalex-snapshot
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia
inferredcites →https://doi.org/10.1186/1479-5876-9-192openalex-snapshot
Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway
inferredcites →https://doi.org/10.1200/jco.2005.06.118openalex-snapshot
Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: Inhibition of Promoter-Specific and Global Genomic DNA Methylation
inferredcites →https://doi.org/10.1200/jco.2005.16.600openalex-snapshot
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
inferredcites →https://doi.org/10.1200/jco.2007.12.6029openalex-snapshot
Combining Epigenetic and Cytotoxic Therapy in the Treatment of Solid Tumors
inferredcites →https://doi.org/10.4161/cbt.2.2.349openalex-snapshot
Calpains Can Do It Alone: Implications for Cancer Therapy
inferredcites →https://doi.org/10.4161/cc.3.6.927openalex-snapshot
Histone-Deacetylase Inhibitors for the Treatment of Cancer

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4129851openalex-extracted
inferred← citeshttps://doi.org/10.1002/cam4.862openalex-snapshot
A phase I trial of panobinostat ( LBH 589) in patients with metastatic melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-21477-7_8openalex-snapshot
Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy
inferred← citeshttps://doi.org/10.1007/s00210-023-02461-1openalex-snapshot
Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma
inferred← citeshttps://doi.org/10.1007/s00394-019-01925-6openalex-snapshot
Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma
inferred← citeshttps://doi.org/10.1007/s10014-015-0221-9openalex-snapshot
Involvement of epimutations in meningioma
inferred← citeshttps://doi.org/10.1007/s11060-020-03461-4openalex-snapshot
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
inferred← citeshttps://doi.org/10.1016/b978-0-12-822522-6.00018-7openalex-snapshot
Potential of naso-brain drug delivery in glioblastoma therapy
inferred← citeshttps://doi.org/10.1016/bs.acr.2016.01.007openalex-snapshot
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
inferred← citeshttps://doi.org/10.1016/bs.acr.2025.08.002openalex-snapshot
Epigenetic mechanisms and therapeutic advances in breast cancer: From molecular insights to clinical applications
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2024.12.001openalex-snapshot
Phytochemicals with epigenetic properties and their role in melanoma therapy
inferred← citeshttps://doi.org/10.1016/j.ajpath.2016.01.020openalex-snapshot
TET2 Negatively Regulates Nestin Expression in Human Melanoma
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.189066openalex-snapshot
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.114886openalex-snapshot
Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses
inferred← citeshttps://doi.org/10.1016/j.blre.2016.02.002openalex-snapshot
Epigenetics: A primer for clinicians
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2023.106602openalex-snapshot
Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2018.11.002openalex-snapshot
Advanced stage melanoma therapies: Detailing the present and exploring the future
inferred← citeshttps://doi.org/10.1016/j.ctrv.2017.01.004openalex-snapshot
Clinical and biological effects of demethylating agents on solid tumours – A systematic review
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2018.02.006openalex-snapshot
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2022.108301openalex-snapshot
Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises
inferred← citeshttps://doi.org/10.1016/j.phrs.2021.105702openalex-snapshot
Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies
inferred← citeshttps://doi.org/10.1016/j.tranon.2025.102452openalex-snapshot
Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.5b00167openalex-snapshot
An HDAC-Targeted Imaging Probe LBH589–Cy5.5 for Tumor Detection and Therapy Evaluation
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.8b01065openalex-snapshot
Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1–/FOXM1+ Triple Negative Breast Cancer Cells
inferred← citeshttps://doi.org/10.1080/09546634.2018.1473550openalex-snapshot
Epigenetic therapy and dermatologic disease: moving beyond CTCL
inferred← citeshttps://doi.org/10.1080/13543776.2016.1209488openalex-snapshot
DNA methyltransferase inhibitors: an updated patent review (2012-2015)
inferred← citeshttps://doi.org/10.1080/13543784.2019.1558442openalex-snapshot
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
inferred← citeshttps://doi.org/10.1080/14728214.2016.1184644openalex-snapshot
Emerging targeted therapies for melanoma
inferred← citeshttps://doi.org/10.1080/15592294.2019.1640546openalex-snapshot
Epidrugs: targeting epigenetic marks in cancer treatment
inferred← citeshttps://doi.org/10.1097/md.0000000000024558openalex-snapshot
Prognostic factors for postoperative survival in melanoma patients with bone metastasis
inferred← citeshttps://doi.org/10.1111/exd.13089openalex-snapshot
Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside
inferred← citeshttps://doi.org/10.1155/2015/481782openalex-snapshot
Cellular Mechanisms of Oxidative Stress and Action in Melanoma
inferred← citeshttps://doi.org/10.1158/0008-5472.can-15-2680openalex-snapshot
Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance
inferred← citeshttps://doi.org/10.1186/s13148-015-0157-2openalex-snapshot
Epigenetic treatment of solid tumours: a review of clinical trials
inferred← citeshttps://doi.org/10.1186/s13148-026-02073-5openalex-snapshot
Advances in epigenetic therapy for esophageal cancer
inferred← citeshttps://doi.org/10.14299/ijser.2016.10.007openalex-snapshot
The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells
inferred← citeshttps://doi.org/10.17760/d20316323openalex-snapshot
Engineering lipid nanoparticles to deliver drug combinations to improve therapeutic efficacy in triple negative breast cancer
inferred← citeshttps://doi.org/10.2217/epi-2016-0046openalex-snapshot
Imprinting Defects in Osteosarcoma: DNA- and Chromatin-Modifying Drugs Hold Promise for Osteosarcoma Therapy
inferred← citeshttps://doi.org/10.2217/epi.15.77openalex-snapshot
Epigenomic Landscape of Melanoma Progression to Brain Metastasis: Unexplored Therapeutic Alternatives
inferred← citeshttps://doi.org/10.2217/fon-2020-0151openalex-snapshot
Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review
inferred← citeshttps://doi.org/10.2217/nnm-2017-0145openalex-snapshot
New Strategies in Melanoma Therapy: Can Nanoparticles Overcome Chemoresistance?
inferred← citeshttps://doi.org/10.31083/fbl42831openalex-snapshot
Histone Modification Networks Reshape the Metabolism and Treatment Landscape of Urological Cancers
inferred← citeshttps://doi.org/10.31083/j.fbl2908287openalex-snapshot
Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications
inferred← citeshttps://doi.org/10.3171/2020.7.jns193097openalex-snapshot
Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT
inferred← citeshttps://doi.org/10.31917/2303170openalex-snapshot
Epigenetics: perspectives of targeted therapy
inferred← citeshttps://doi.org/10.3389/fimmu.2015.00029openalex-snapshot
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
inferred← citeshttps://doi.org/10.3389/fonc.2015.00183openalex-snapshot
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
inferred← citeshttps://doi.org/10.3389/fonc.2024.1464125openalex-snapshot
Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects
inferred← citeshttps://doi.org/10.3390/biomedicines10030517openalex-snapshot
The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation
inferred← citeshttps://doi.org/10.3390/cancers11091342openalex-snapshot
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
inferred← citeshttps://doi.org/10.3390/cancers13092241openalex-snapshot
The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
inferred← citeshttps://doi.org/10.3390/cancers13133209openalex-snapshot
Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments
inferred← citeshttps://doi.org/10.3390/cancers13174363openalex-snapshot
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
inferred← citeshttps://doi.org/10.3390/cancers13246180openalex-snapshot
Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
inferred← citeshttps://doi.org/10.3390/cells10051225openalex-snapshot
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
inferred← citeshttps://doi.org/10.3390/cells10082048openalex-snapshot
Epigenetic Regulation in Melanoma: Facts and Hopes
inferred← citeshttps://doi.org/10.3390/epigenomes1010003openalex-snapshot
New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know
inferred← citeshttps://doi.org/10.3390/ijms21155314openalex-snapshot
Targeting Epigenetic Modifications in Uveal Melanoma
inferred← citeshttps://doi.org/10.3390/ijms23073660openalex-snapshot
Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
inferred← citeshttps://doi.org/10.3390/ijms232214042openalex-snapshot
Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy
inferred← citeshttps://doi.org/10.3390/jpm11090901openalex-snapshot
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2020.02.04openalex-snapshot
[Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors].
inferred← citeshttps://doi.org/10.3892/ijo.2022.5424openalex-snapshot
Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
inferred← citeshttps://doi.org/10.4081/oncol.2019.417openalex-snapshot
Current promising treatment strategy for glioblastoma multiform: A review
inferred← citeshttps://doi.org/10.5772/64733openalex-snapshot
The Emerging Epigenetic Landscape in Melanoma
inferred← citeshttps://doi.org/10.70675/4e035d32zbda7z4539z8911z00e1344b619fopenalex-snapshot
Etude de CD160, récepteur activateur des cellules NK dans le mélanome : une potentielle cible thérapeutique à l'ère de l'immunothérapie ?
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.